Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| U.S. | | | | 10,839.0 | 9,673.0 | | | |
| Diagnostics | 15,644.0 | 10,805.0 | 7,713.0 | 7,495.0 | 5,616.0 | | 4,646.0 | 4,721.0 |
| Nutritionals | 8,294.0 | 7,647.0 | 7,409.0 | 7,229.0 | 6,925.0 | | 6,975.0 | 6,953.0 |
| Established Pharmaceuticals | 4,718.0 | 4,303.0 | 4,486.0 | 4,422.0 | 4,287.0 | | 3,720.0 | 3,118.0 |
| Other | 14,419.0 | 11,853.0 | 12,296.0 | 593.0 | 889.0 | | 5,064.0 | 5,455.0 |
| Total revenues [+] | 43,075.0 | 34,608.0 | 31,904.0 | 30,578.0 | 27,390.0 | 20,853.0 | 20,405.0 | 20,247.0 |
| Products | 43,075.0 | 34,608.0 | 31,904.0 | 30,578.0 | 27,390.0 | 20,853.0 | | |
| Revenue growth [+] | 24.5% | 8.5% | 4.3% | 11.6% | 31.3% | 2.2% | 0.8% | 3.0% |
| U.S. | | | | 12.1% | | | | |
| Diagnostics | 44.8% | 40.1% | 2.9% | 33.5% | | | -1.6% | 3.9% |
| Nutritionals | 8.5% | 3.2% | 2.5% | 4.4% | | | 0.3% | 3.2% |
| Established Pharmaceuticals | 9.6% | -4.1% | 1.4% | 3.1% | | | 19.3% | 8.9% |
| Other | | | | -73.8% | | | -8.0% | -1.2% |
| Cost of goods sold | 18,537.0 | 15,003.0 | 13,231.0 | 12,706.0 | 12,409.0 | 9,094.0 | 8,747.0 | 9,218.0 |
| Gross profit | 24,538.0 | 19,605.0 | 18,673.0 | 17,872.0 | 14,981.0 | 11,759.0 | 11,658.0 | 11,029.0 |
| Gross margin | 57.0% | 56.6% | 58.5% | 58.4% | 54.7% | 56.4% | 57.1% | 54.5% |
| Selling, general and administrative | 11,324.0 | 9,696.0 | 9,765.0 | 9,744.0 | 9,182.0 | 6,736.0 | 6,785.0 | 6,530.0 |
| Research and development | 2,742.0 | 2,420.0 | 2,440.0 | 2,300.0 | 2,260.0 | 1,447.0 | 1,405.0 | 1,345.0 |
| Equity in earnings | | | | | | | | |
| Other operating expenses | 2,047.0 | 2,132.0 | 1,936.0 | 2,178.0 | 1,975.0 | 550.0 | 601.0 | 555.0 |
| EBITDA [+] | 11,963.0 | 8,684.0 | 7,546.0 | 6,928.0 | 4,585.0 | 4,379.0 | 4,339.0 | 4,147.0 |
| EBITDA growth | 37.8% | 15.1% | 8.9% | 51.1% | 4.7% | 0.9% | 4.6% | 7.7% |
| EBITDA margin | 27.8% | 25.1% | 23.7% | 22.7% | 16.7% | 21.0% | 21.3% | 20.5% |
| Depreciation | 1,491.0 | 1,195.0 | 1,078.0 | 1,100.0 | 1,046.0 | 803.0 | 871.0 | 918.0 |
| EBITA | 10,472.0 | 7,489.0 | 6,468.0 | 5,828.0 | 3,539.0 | 3,576.0 | 3,468.0 | 3,229.0 |
| EBITA margin | 24.3% | 21.6% | 20.3% | 19.1% | 12.9% | 17.1% | 17.0% | 15.9% |
| Amortization of intangibles | 2,047.0 | 2,132.0 | 1,936.0 | 2,178.0 | 1,975.0 | 550.0 | 601.0 | 630.0 |
| EBIT [+] | 8,425.0 | 5,357.0 | 4,532.0 | 3,650.0 | 1,564.0 | 3,026.0 | 2,867.0 | 2,599.0 |
| EBIT growth | 57.3% | 18.2% | 24.2% | 133.4% | -48.3% | 5.5% | 10.3% | 21.8% |
| EBIT margin | 19.6% | 15.5% | 14.2% | 11.9% | 5.7% | 14.5% | 14.1% | 12.8% |
| Interest expense, net [+] | 490.0 | 500.0 | 576.0 | 721.0 | 780.0 | 332.0 | 58.0 | 73.0 |
| Interest expense | 533.0 | 546.0 | 670.0 | 826.0 | 904.0 | 431.0 | 163.0 | 150.0 |
| Interest income | 43.0 | 46.0 | 94.0 | 105.0 | 124.0 | 99.0 | 105.0 | 77.0 |
| Other income (expense), net [+] | 276.0 | 111.0 | 121.0 | -56.0 | 1,447.0 | -1,281.0 | 374.0 | -8.0 |
| Gain (loss) on debt retirement | | | -63.0 | -167.0 | | | | 18.0 |
| Gain (loss) on foreign currency transactions | 1.0 | -8.0 | 7.0 | 28.0 | -34.0 | 495.0 | -93.0 | -24.0 |
| Other | 277.0 | 103.0 | 191.0 | 139.0 | 1,413.0 | -786.0 | 281.0 | -14.0 |
| Pre-tax income | 8,211.0 | 4,968.0 | 4,077.0 | 2,873.0 | 2,231.0 | 1,413.0 | 3,183.0 | 2,518.0 |
| Income taxes | 1,140.0 | 497.0 | 390.0 | 539.0 | 1,878.0 | 350.0 | 577.0 | 797.0 |
| Tax rate | 13.9% | 10.0% | 9.6% | 18.8% | 84.2% | 24.8% | 18.1% | 31.7% |
| Earnings from continuing ops | 7,071.0 | 4,447.0 | 3,687.0 | 2,300.0 | 229.0 | 726.0 | 789.0 | 1,158.0 |
| Earnings from discontinued ops | | 24.0 | | 34.0 | 124.0 | 337.0 | 1,817.0 | 563.0 |
| Net income | 7,071.0 | 4,471.0 | 3,687.0 | 2,334.0 | 353.0 | 1,063.0 | 2,606.0 | 1,721.0 |
| Net margin | 16.4% | 12.9% | 11.6% | 7.6% | 1.3% | 5.1% | 12.8% | 8.5% |
| |
| Basic EPS [+] | $3.98 | $2.51 | $2.09 | $1.31 | $0.13 | $0.49 | $0.53 | $0.76 |
| Growth | 58.8% | 20.3% | 59.4% | 894.1% | -73.2% | -6.8% | -31.0% | -15.0% |
| Diluted EPS [+] | $3.95 | $2.49 | $2.07 | $1.30 | $0.13 | $0.49 | $0.52 | $0.76 |
| Growth | 58.7% | 20.3% | 59.3% | 892.5% | -73.3% | -6.6% | -30.9% | -14.7% |
| |
| Dividends per share [+] | $1.80 | $1.44 | $1.28 | $1.12 | $1.06 | $1.04 | $0.96 | $0.89 |
| Growth | 24.9% | 12.5% | 14.3% | 5.7% | 2.0% | 8.0% | 9.0% | 56.4% |
| |
| Shares outstanding (basic) [+] | 1,775.0 | 1,773.0 | 1,768.0 | 1,758.0 | 1,740.0 | 1,477.0 | 1,496.0 | 1,516.0 |
| Growth | 0.1% | 0.3% | 0.6% | 1.0% | 17.8% | -1.3% | -1.3% | -2.7% |
| Shares outstanding (diluted) [+] | 1,789.0 | 1,786.0 | 1,781.0 | 1,770.0 | 1,749.0 | 1,483.0 | 1,506.0 | 1,527.0 |
| Growth | 0.2% | 0.3% | 0.6% | 1.2% | 17.9% | -1.5% | -1.4% | -3.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|